Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PF 04217903

Known as: MET Tyrosine Kinase Inhibitor PF-04217903, PF-04217903, PF04217903 
An orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity. MET tyrosine kinase inhibitor PF-04217903… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Oncogenic gene fusions have been identified in many cancers and many serve as biomarkers or targets for therapy. Here we identify… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
Epithelial ovarian cancer (EOC) metastasizes transcoelomically to the peritoneum and omentum, and despite surgery and… Expand
Highly Cited
2013
Highly Cited
2013
Inhibition of VEGF signaling can promote lymph node metastasis in preclinical models, but the mechanism is not fully understood… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2012
Highly Cited
2012
UNLABELLED Invasion and metastasis increase after the inhibition of VEGF signaling in some preclinical tumor models. In the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2012
Highly Cited
2012
The c-Met pathway has been implicated in a variety of human cancers for its critical role in tumor growth, invasion, and… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2012
Highly Cited
2012
The c-MET receptor tyrosine kinase is an attractive oncology target because of its critical role in human oncogenesis and tumor… Expand
2012
2012
Targeting cancers with amplified or abnormally activated c-Met (hepatocyte growth factor receptor) may have therapeutic benefit… Expand
Highly Cited
2011
Highly Cited
2011
The objective of this study was to assess the physiologically based pharmacokinetic (PBPK) model for predicting plasma… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2011
2011
In recent years, there have been notable advances with the development of anticancer drugs including those targeting protein… Expand
Highly Cited
2009
Highly Cited
2009
The c-Met receptor tyrosine kinase (RTK) is a key regulator in cancer, in part, through oncogenic mutations. Eight clinically… Expand